Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
The revised outlook is primarily due to slower than anticipated revenue recognition from the SK On agreements the company entered into earlier this year and, to a lesser extent, delays in forecasted electrolyte sales, rather than a decline in contracted business.
The company continues to expect 2024 cash used in operations to be in the range of $60 million to $70 million and capital expenditures to be in the range of $40 million to $50 million.
Posted In: SLDP